Type 2 Diabetes

FIGARO-DKD concluded use of finerenone was associated with a 13% reduction in the primary outcome, which investigators purport demonstrates the benefit of finerenone use in a population with milder chronic kidney disease than those included in FIDELIO-DKD.

The updated USPSTF recommends screening for prediabetes and type 2 diabetes in adults aged 35 - 75 years with conditions including overweight or obesity.

The US Preventive Services Task Force has issued a B-graded recommendation statement lowering their recommended age for screening for type 2 diabetes from 40 to 35 years.

Data from the SEARCH for Diabetes in Youth Study suggests the prevalence of type 1 diabetes among youths have increased by nearly 50% from 2001-2017 and prevalence of type 2 diabetes increased by more than 95% during the same period.

New data suggests patients with a history of diabetes, hypertension, or cardiovascular disease were at increased risk of worsening hypoxemia compared to their counterparts without these conditions.

A new meta-analysis by investigators from Johns Hopkins details the prevalence of UACR testing in patient populations at increased risk of albuminuria, suggesting less than 40% of patients with diabetes underwent UACR testing and this figure dropped to less than 5% among patients with hypertension.

A review article details the prevalence and impact of sleep disorders in patients with type 2 diabetes as well as providing an overview current treatment options and research needs.

Most common factor for hospitalizations of T2D include cardiac disorder, infections and infestations, and nervous system disorders.

An analysis of registry data from more than 2.4 million births in Denmark suggests those born to mothers with diabetes were 39% more likely to experience high refractive error before turning 25 years old.

A recent study published in JAMA details increasing rates of gestational diabetes among first-time mothers in the US from 2011-2019, with rates increasing across all racial/ethnic subgroups examined in the 12 million person analysis.

A substudy of a prospective observational study performed at a hospital in Italy details potential associations of vitamin D levels with BMI and blood glucose and severity of COVID-19.

Eli Lilly and Company announced the FDA has expanded the label of insulin lispro-aabc injection (Lyumjev) to allow for administration via insulin pumps.

The treatment controls blood sugar levels after meals in adults with type 1 and type 2 diabetes.

The study notes the importance of follow-up monitoring of sleep apnea in patients with IH.

An analysis of data from a national health database in South Korea suggests increased BMI variability was linked to a 66% greater risk of mortality and a 19% greater risk of heart attack and stroke in patients with chronic kidney disease.

A systematic review and meta-analysis of randomized clinical trial data suggest those adhering to diets with a low glycemic index and low glycemic load were linked to lowered HbA1c levels and improvements in cardiometabolic risk factors.

An analysis of the ARIC study suggests patients with diabetes had a 67% greater risk of hospitalization for infection than their counterparts without diabetes.

The latest recommendation statement reaffirms the USPSTF's 2014 guidance, which included a B recommendation for screening for gestational diabetes at 24 weeks of gestation or after.

Data show moderate net benefit for screening at 24 weeks of gestation or after, but there is insufficient evidence to assess benefit of screening before 24 weeks.

In an analysis, low GI/GL dietary patterns resulted in a reduction in HbA1c, compared with control diets with a mean difference of −0.31.

A secondary analysis of the D2d study provides evidence suggesting vitamin D supplementation in patients with prediabetes provided no significant benefit on kidney outcomes from within the study.

Patients with metabolic syndrome were at a 46% increased risk of a second stroke and a 27% increased risk of mortality when compared to their counterparts without metabolic syndrome.

The final portion of our 3-part series on insulin affordability in 2021, a clinical pharmacy specialist and a nurse practitioner discuss how recent developments impact the cost of insulin and whether "Insulin for All" is a meaningful phrase or wishful thinking.

A clinical pharmacist and nurse practitioner offer perspective on how the interchangeable biosimilar approval of Semglee impacts discussions around the cost of insulin for patients with diabetes and what they think is important for patients, providers, and pharmacists to know about the historic FDA approval.

Diana Isaacs, PharmD, a clinical pharmacy specialist, and Lucia Novak, CRNP, a nurse practitioner, have a discussion centered around how Walmart's recent launch of ReliOn NovoLog impacts the landscape of diabetes management and insulin affordability.